Identification of two clusters within schizophrenia with different structural, functional and clinical characteristics

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 79-86

  Lubeiro, Alba ^a   Rueda, Cristina ^b   Hernández, Juan A ^d   Sanz, Javier ^c,e   Sarramea, Fernando ^f   Molina, Vicente ^a,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Clusters; Curvature; Heterogeneity; Magnetic resonance imaging; Schizophrenia; Thickness

Indexed keywords

ADULT; ARTICLE; BIPOLAR DISORDER; BRAIN METABOLISM; BRAIN SIZE; CINGULATE GYRUS; CLINICAL FEATURE; CONTROLLED STUDY; CORTICAL CURVATURE; CORTICAL THICKNESS (BRAIN); EVENT RELATED POTENTIAL; FEMALE; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NERVOUS SYSTEM PARAMETERS; NEUROANATOMY; SCHIZOPHRENIA; SUBCORTEX; THALAMUS; ACUTE DISEASE; BRAIN; CHRONIC DISEASE; CLASSIFICATION; FOLLOW UP; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGICAL RATING SCALE; REST; SCINTISCANNING; VALIDATION STUDY;

GLUCOSE;

ACUTE DISEASE; ADULT; BIPOLAR DISORDER; BRAIN; CHRONIC DISEASE; EVENT-RELATED POTENTIALS, P300; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; REST; SCHIZOPHRENIA;

EID: 84938252202     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.06.015     Document Type: Article

References (40)

1. Arnedo J., Svrakic D.M., Del Val C., Romero-Zaliz R., Hernandez-Cuervo H., Fanous A.H., et al. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am. J. Psychiatry 2014, 172:139-153.
2. Bartlett E.J., Brodie J.D., Simkowitz P., Dewey S.L., Rusinek H., Wolf A.P., et al. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am. J. Psychiatry 1994, 151:681-686.
3. Blasi G., Napolitano F., Ursini G., Di Giorgio A., Caforio G., Taurisano P., et al. Association of GSK-3beta genetic variation with GSK-3beta expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. Am. J. Psychiatry 2013, 170:868-876.
4. Cachia A., Paillere-Martinot M.L., Galinowski A., Januel D., de Beaurepaire R., Bellivier F., et al. Cortical folding abnormalities in schizophrenia patients with resistant auditory hallucinations. NeuroImage 2008, 39:927-935.
5. Cassidy C., Buchy L., Bodnar M., Dell'elce J., Choudhry Z., Fathalli F., et al. Association of a risk allele of ANK3 with cognitive performance and cortical thickness in patients with first-episode psychosis. J. Psychiatry Neurosci. 2014, 39:31-39.
6. Crespo-Facorro B., Roiz-Santianez R., Perez-Iglesias R., Rodriguez-Sanchez J.M., Mata I., Tordesillas-Gutierrez D., et al. Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features. Psychol. Med. 2011, 41:1449-1460.
7. Crow T.J. The two-syndrome concept: origins and current status. Schizophr. Bull. 1985, 11:471-486.
8. Deppe M., Marinell J., Krämer J., Dunning T., Ruck T., Simon O.J., et al. Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. NeuroImage Clin. 2014, 6:475-487.
9. Falkai P., Honer W.G., Kamer T., Dustert S., Vogeley K., Schneider-Axmann T., et al. Disturbed frontal gyrification within families affected with schizophrenia. J. Psychiatr. Res. 2007, 41:805-813.
10. Fornito A., Yucel M., Wood S.J., Adamson C., Velakoulis D., Saling M.M., et al. Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Hum. Brain Mapp. 2008, 29:478-489.
11. Fornito A., Zalesky A., Pantelis C., Bullmore E.T. Schizophrenia, neuroimaging and connectomics. NeuroImage 2012, 62:2296-2314.
12. Fujimoto T., Takeuch K., Matsumoto T., Kamimura K., Hamada R., Nakamura K., et al. Abnormal glucose metabolism in the anterior cingulate cortex in patients with schizophrenia. Psychiatry Res. 2007, 154:49-58.
13. Goldman A.L., Pezawas L., Mattay V.S., Fischl B., Verchinski B.A., Chen Q., et al. Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Arch. Gen. Psychiatry 2009, 66:467-477.
14. Harris J.M., Yates S., Miller P., Best J.J., Johnstone E.C., Lawrie S.M. Gyrification in first-episode schizophrenia: a morphometric study. Biol. Psychiatry 2004, 55:141-147.
15. Haznedar M.M., Buchsbaum M.S., Hazlett E.A., Shihabuddin L., New A., Siever L.J. Cingulate gyrus volume and metabolism in the schizophrenia spectrum. Schizophr. Res. 2004, 71:249-262.
16. Ho B.C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68:128-137.
17. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
18. Molina Rodriguez V., Montz Andree R., Perez Castejon M.J., Capdevila Garcia E., Carreras Delgado J.L., Rubia Vila F.J. SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. Am. J. Psychiatry 1996, 153:1343-1346.
19. Molina V., Gispert J.D., Reig S., Sanz J., Pascau J., Santos A., et al. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophr. Res. 2003, 60:1-7.
20. Molina V., Reig S., Sarramea F., Sanz J.F., Artaloytia J., Luque R., et al. Anatomical and functional brain variables associated to clozapine response in treatment-resistant schizophrenia. Psychiatry Res. Neuroimaging 2003, 124:153-161.
21. Molina V., Reig S., Desco M., Pascau J., Sanchez J., Palomo T., et al. Increase in gray matter volume and decrease in white matter volume in the cerebral cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr. Bull. 2005, 31:400-.
22. Molina V., Sanz J., Muñoz F., Casado P., Hinojosa J.A., Sarramea F., et al. Dorsolateral prefrontal cortex contribution to p300 abnormalities in schizophrenia. Psychiatry Res. Neuroimaging 2005, 140:17-26.
23. Molina V., Galindo G., Cortes B., Hernandez J.A. Voxel-based morphometry comparison between chronic schizophrenia and bipolar patients and healthy controls. Schizophr. Res. 2010, 341-.
24. Molina V., Hernandez J.A., Sanz J., Paniagua J.C., Hernandez A.I., Martin C., et al. Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry. Psychiatry Res. 2010, 184:16-22.
25. Papiol S., Molina V., Desco M., Rosa A., Reig S., Gispert J.D., et al. Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. NeuroImage 2005, 27:1002-1006.
26. Piao X., Hill R.S., Bodell A., Chang B.S., Basel-Vanagaite L., Straussberg R., et al. G protein-coupled receptor-dependent development of human frontal cortex. Science 2004, 303:2033-2036.
27. Rimol L.M., Nesvag R., Hagler D.J., Bergmann O., Fennema-Notestine C., Hartberg C.B., et al. Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. Biol. Psychiatry 2012, 71:552-560.
28. Ripke S., O'Dushlaine C., Chambert K., Moran J.L., Kahler A.K., Akterin S., et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 2013, 45:1150-1159.
29. Ronan L., Pienaar R., Williams G., Bullmore E., Crow T.J., Roberts N., et al. Intrinsic curvature: a marker of millimeter-scale tangential cortico-cortical connectivity?. Int. J. Neural Syst. 2011, 21:351-366.
30. Ronan L., Voets N.L., Hough M., Mackay C., Roberts N., Suckling J., et al. Consistency and interpretation of changes in millimeter-scale cortical intrinsic curvature across three independent datasets in schizophrenia. NeuroImage 2012, 63:611-621.
31. Schmitt J.E., Neale M.C., Fassassi B., Perez J., Lenroot R.K., Wells E.M., et al. The dynamic role of genetics on cortical patterning during childhood and adolescence. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:6774-6779.
32. Szeszko P.R., Narr K.L., Phillips O.R., McCormack J., Sevy S., Gunduz-Bruce H., et al. Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophr. Bull. 2012, 38:569-578.
33. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
34. Van Essen D.C. A tension-based theory of morphogenesis and compact wiring in the central nervous system. Nature 1997, 385:313-318.
35. Van Haren N.E., Schnack H.G., Cahn W., van den Heuvel M.P., Lepage C., Collins L., et al. Changes in cortical thickness during the course of illness in schizophrenia. Arch. Gen. Psychiatry 2011, 68:871-880.
36. Venkatasubramanian G., Jayakumar P.N., Gangadhar B.N., Keshavan M.S. Automated MRI parcellation study of regional volume and thickness of prefrontal cortex (PFC) in antipsychotic-naive schizophrenia. Acta Psychiatr. Scand. 2008, 117:420-431.
37. White T., Hilgetag C.C. Gyrification of the human brain. Developmental Cognitive Neuroscience 2008, MIT Press, Cambridge, MA. C.A. Nelson, M. Luciana (Eds.).
38. White T., Hilgetag C.C. Gyrification and neural connectivity in schizophrenia. Dev. Psychopathol. 2011, 23:339-352.
39. Whittle S., Simmons J.G., Dennison M., Vijayakumar N., Schwartz O., Yap M.B., et al. Positive parenting predicts the development of adolescent brain structure: a longitudinal study. Dev. Cogn. Neurosci. 2014, 8:7-17.
40. Wolkin A., Sanfilipo M., Duncan E., Angrist B., Wolf A.P., Cooper T.B., et al. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. Am. J. Psychiatry 1996, 153:346-354.